Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. (Q55055249)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Thierry J Molina

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

René-Olivier Casasnovas

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Christian Récher

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Bertrand Coiffier

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Corinne Haioun

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Christophe Fermé

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Catherine Thiéblemont

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

André Bosly

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Guy Laurent

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Franck Morschhauser

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Hervé Ghesquières

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Fabrice Jardin

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Serge Bologna

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Christophe Fruchart

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Bernadette Corront

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Jean Gabarre

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Christophe Bonnet

17

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Maud Janvier

18

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Danielle Canioni

19

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Jean-Philippe Jais

20

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Hervé Tilly

22

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Groupe d'Etude des Lymphomes de l'Adulte

23

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Gilles Salles

21

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

language of work or name

0 references

publication date

1 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

378

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

9806

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1858-1867

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo I

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intensive and sequential combination chemotherapy for aggressive malignant lymphomas (protocol LNH-80)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Intravenous methotrexate as central nervous system (CNS) prophylaxis is associated with a low risk of CNS recurrence in high-risk patients with diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Factors predictive of early death in patients receiving high-dose CHOP (ACVB regimen) for aggressive non-Hodgkin's lymphoma: a GELA study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

DNA damage-mediated induction of a chemoresistant niche

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Rituximab: mechanism of action

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Aggressive lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2961040-4

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0140-6736(11)61040-4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22118442%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55055249&oldid=1561065328"